Anne Douar, Chief Development Officer of Vivet Therapeutics, will give a presentation (“Manufacturing of a New Gene Therapy Product: Long Term Impact from Early Decision to Selection for Phase I to BLA / Commercial Strategy”) during the 3rd Annual Gene Therapy for Rare Disorders Europe conference in London on Oct. 16th at 11.15am
VIVET PRESENTING DURING 2019 GENE THERAPY FOR RARE DISORDERS EUROPE CONFERENCE IN LONDON
Vivet Therapeutics → Events → VIVET PRESENTING DURING 2019 GENE THERAPY FOR RARE DISORDERS EUROPE CONFERENCE IN LONDON